How the Mighty Have Fallen, and the Skinny on Lilly 8/7/23
CNBC's "Fast Money"
00:00
Eli Lilly's Q2 Report
Jared Holes, a healthcare sector specialist at Mizuho Security: The bar is high. If it does hit statistically significant, which is probably somewhere in the range of 15 to 20%, then I think the stocks go up 5 to 10%. They are obviously pricing in a lot here. And as far as not taking the drug forever, for example, with Coca-Cola, maybe they'll start making better choices and less Doritos,. That's the hope right now that we start acting better on some point.
Play episode from 35:57
Transcript
